Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1,158.11
- Piotroski Score 1.00
- Grade Buy
- Symbol (INKT)
- Company MiNK Therapeutics, Inc.
- Price $0.72
- Changes Percentage (-1.36%)
- Change -$0.01
- Day Low $0.72
- Day High $0.75
- Year High $1.90
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.59
- Trailing P/E Ratio -1.63
- Forward P/E Ratio -1.63
- P/E Growth -1.63
- Net Income $-22,457,859
Income Statement
Quarterly
Annual
Latest News of INKT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bring in pay-per-mile road pricing system across UK, urges Tony Blair's thinktank
Rachel Reeves is urged to shelve fuel duty plans and reform taxes as UK transitions to electric vehicles. A pay-per-mile road pricing system is recommended by Tony Blair's thinktank to generate revenu...
By The Guardian | 1 week ago -
Thinktanks issue UK 'wake-up' call to danger posed by scientific racism
The Guardian and Hope Not Hate's investigation has highlighted the rising threat of right-wing ideology promoting scientific racism. Think tanks urge health institutions to address this danger, emphas...
By The Guardian | 2 weeks ago -
UK must stop being naive over resetting relations with EU, thinktank says
The European Centre for International Political Economy suggests the UK needs to show more flexibility in negotiations with the EU to improve relations. The roadmap outlines key points for a successfu...
By The Guardian | 1 month ago
